Evogene (EVGN) Change in Receivables (2013 - 2026)
Evogene (EVGN) posted Change in Receivables of $31000.0 for Q1 2026, up 1650.0% sequentially from -$2000.0 in Q4 2025, and up 102.03% YoY from $15344.5 in Q1 2025.
Evogene (EVGN) Change in Receivables (2013 - 2026) Analysis & Trends
Evogene has reported Change in Receivables for 14 years, with the latest figure at $31000.0 in Q1 2026.
- Quarterly Change in Receivables rose 102.03% year-over-year to $31000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 212.82% YoY) and the FY2025 annual result came in at $665000.0, up 206.06% from the prior year.
- Change in Receivables climbed to $31000.0 in Q1 2026 per EVGN's latest filing, from -$2000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $1.5 million in Q2 2025 and troughed at -$1.5 million in Q1 2025.
- A 5-year average of -$294.12 and a median of $72000.0 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2025: Change in Receivables surged 3733.33% in 2022, then tumbled 740.66% in 2025.
- Over 5 years, Change in Receivables stood at $104000.0 in 2022, then jumped by 850.0% to $988000.0 in 2023, then slumped by 39.17% to $601000.0 in 2024, then tumbled by 100.33% to -$2000.0 in 2025, then surged by 1650.0% to $31000.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $31000.0, -$2000.0, and $730000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 31,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31,000.00 |
| Mar 31, 2026 | 31,000.00 |
| Dec 31, 2025 | -2,000.00 |
| Dec 31, 2025 | -2,000.00 |
| Sep 30, 2025 | 730,000.00 |
| Sep 30, 2025 | 730,000.00 |
| Jun 30, 2025 | 1.47 Mn |
| Jun 30, 2025 | 1.47 Mn |
| Mar 31, 2025 | -1.53 Mn |
| Mar 31, 2025 | -1.53 Mn |
| Dec 31, 2024 | 601,000.00 |
| Dec 31, 2024 | 601,000.00 |
| Sep 30, 2024 | -1.35 Mn |
| Sep 30, 2024 | -1.35 Mn |
| Jun 30, 2024 | 303,000.00 |
| Jun 30, 2024 | 303,000.00 |
| Mar 31, 2024 | -182,000.00 |
| Mar 31, 2024 | -182,000.00 |
| Dec 31, 2023 | 988,000.00 |
| Dec 31, 2023 | 988,000.00 |